The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Recent developments in embolization-eligible unresectable HCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, explores recent developments in embolization-eligible unresectable hepatocellular carcinoma (HCC). Traditionally, these patients would receive transarterial chemoembolization (TACE), however emerging data shows that lenvatinib with PD-1- or CTLA-4-targeted antibodies could improve progression-free survival and response rates, providing another treatment option. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
